Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Operating Leases (2019 - 2025)

X4 Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $95000.0 for Q3 2025.

  • For Q3 2025, Operating Leases fell 94.59% year-over-year to $95000.0; the TTM value through Sep 2025 reached $95000.0, down 94.59%, while the annual FY2024 figure was $1.4 million, 46.02% down from the prior year.
  • Operating Leases reached $95000.0 in Q3 2025 per XFOR's latest filing, down from $2.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.6 million in Q1 2022 to a low of $95000.0 in Q3 2025.
  • Average Operating Leases over 5 years is $3.4 million, with a median of $3.4 million recorded in 2023.
  • Peak YoY movement for Operating Leases: soared 124.32% in 2021, then crashed 94.59% in 2025.
  • A 5-year view of Operating Leases shows it stood at $4.8 million in 2021, then dropped by 24.56% to $3.6 million in 2022, then dropped by 27.5% to $2.6 million in 2023, then tumbled by 46.02% to $1.4 million in 2024, then tumbled by 93.26% to $95000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Operating Leases are $95000.0 (Q3 2025), $2.2 million (Q2 2025), and $2.4 million (Q1 2025).